Patent intelligence · US
US 11266655
Methods and compositions for treating urea cycle disorders
Methods and compositions for treating urea cycle disorders
Patent details — US 11266655
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 8, 2022
- Expiration
- Mar 3, 2042
- Applicant
- CAMP4 Therapeutics Corporation
- Claims
- 10
- CPC classes
- A61K, A61K31/395, A61K31/416, A61K31/519
Quick answer
US 11266655 (Methods and compositions for treating urea cycle disorders) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Mar 8, 2022. Expires Mar 3, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAMP4 Therapeutics Corporation
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/395, A61K31/416, A61K31/519, A61K31/52, A61K31/5377
More from CAMP4 Therapeutics Corporation
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11266655?
US 11266655 (Methods and compositions for treating urea cycle disorders) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Mar 8, 2022. Expires Mar 3, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11266655?
CAMP4 Therapeutics Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11266655 expire?
Our index shows an expiration date of Mar 3, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.